Wells Fargo & Company Trevi Therapeutics, Inc. Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 55,686 shares of TRVI stock, worth $630,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,686

Previous 41,171 35.26%

Holding current value

$630,922

Previous $225,000 120.89%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$5.62 - $9.62 $81,574 - $139,634	14,515 Added 35.26%	55,686 $497,000
Q2 2025 Aug 14, 2025	BUY	$5.28 - $7.06 $396 - $529	75 Added 0.18%	41,171 $225,000
Q1 2025 May 13, 2025	BUY	$3.66 - $6.81 $29,448 - $54,793	8,046 Added 24.34%	41,096 $258,000
Q4 2024 Feb 12, 2025	BUY	$2.53 - $4.5 $24,191 - $43,029	9,562 Added 40.71%	33,050 $140,000
Q3 2024 Nov 13, 2024	BUY	$2.58 - $3.51 $25 - $35	10 Added 0.04%	23,488 $78,000

Q2 2024 Aug 13, 2024	BUY	$2.44 - $3.36 $16,199 - $22,307	6,639 Added 39.43%	23,478 $69,000
Q1 2024 May 10, 2024	BUY	$1.3 - $3.7 $5,040 - $14,344	3,877 Added 29.91%	16,839 $58,000
Q4 2023 Feb 09, 2024	BUY	$1.06 - $2.05 $2,848 - $5,508	2,687 Added 26.15%	12,962 $17,000
Q3 2023 Nov 13, 2023	SELL	$2.11 - $2.47 $11,735 - $13,738	-5,562 Reduced 35.12%	10,275 $22,000
Q2 2023 Aug 15, 2023	BUY	$1.8 - $3.44 $28,029 - $53,567	15,572 Added 5876.23%	15,837 $37,000
Q1 2023 May 12, 2023	BUY	$1.69 - $2.97 $6 - $11	4 Added 1.53%	265 $0
Q4 2022 Feb 13, 2023	BUY	$1.61 - $2.42 $196 - $295	122 Added 87.77%	261 $0
Q3 2022 Nov 14, 2022	SELL	$1.54 - $4.28 $41 - $115	-27 Reduced 16.27%	139 $0
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.39 $167 - $315	93 Added 127.4%	166 $0
Q4 2021 Feb 14, 2022	BUY	$0.68 - $1.5 $18 - $40	27 Added 58.7%	73 $0
Q3 2021 Nov 15, 2021	BUY	$1.29 - $2.18 $16 - $28	13 Added 39.39%	46 $0
Q2 2021 Aug 16, 2021	BUY	$2.0 - $2.76 $18 - $24	9 Added 37.5%	33 $0
Q1 2021 May 13, 2021	BUY	$2.36 - $3.55 $4 - $7	2 Added 9.09%	24 $0
Q3 2020 Nov 05, 2020	SELL	$3.5 - $7.62 $49 - $106	-14 Reduced 38.89%	22 $0
Q1 2020 May 14, 2020	BUY	$1.71 - $5.87 $61 - $211	36 New	36 $0

Others Institutions Holding TRVI

# of Institutions

174

Shares Held

119M

Call Options Held

629K

Put Options Held

1.22M

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $661M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Trevi Therapeutics, Inc. Transaction History